Literature DB >> 4632435

Long-term treatment of multiple sclerosis with azathioprine.

W R Swinburn, L A Liversedge.   

Abstract

Nineteen patients with multiple sclerosis were treated with azathioprine for two years. There was no evidence that treatment prevented deterioration or reduced the number or severity of the relapses when compared with 24 control patients observed over the same period.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4632435      PMCID： PMC494286          DOI： 10.1136/jnnp.36.1.124

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  7 in total

1.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

2.  Multiple sclerosis: pilot therapeutic trial of immunosuppressants.

Authors:  W S Cendrowski
Journal:  Schweiz Arch Neurol Neurochir Psychiatr       Date:  1969

3.  Long-term treatment of multiple sclerosis with corticotrophin.

Authors:  J H Millar; C J Vas; M J Noronha; L A Liversedge; M D Rawson
Journal:  Lancet       Date:  1967-08-26       Impact factor: 79.321

4.  [Immunosuppressive therapy of multiple sclerosis. 1. Preliminary communication on the results of treatment with azathioprine and anti-lymphocytic globulin].

Authors:  E Frick; H Angstwurm; G Späth
Journal:  Munch Med Wochenschr       Date:  1971-02-12

Review 5.  Azathioprine therapy of "autoimmune" diseases.

Authors:  C C Corley; H E Lessner; W E Larsen
Journal:  Am J Med       Date:  1966-09       Impact factor: 4.965

6.  A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis.

Authors:  W G Tucker; K H Kapphahn
Journal:  Henry Ford Hosp Med J       Date:  1969

7.  Therapeutic trial of Imuran (azathioprine) in multiple sclerosis.

Authors:  W S Cendrowski
Journal:  Acta Neurol Scand       Date:  1971       Impact factor: 3.209
  7 in total
  15 in total

1.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

2.  Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.

Authors:  E M Lance; M Kremer; J Abbosh; V E Jones; S Knight; P B Medawar
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

3.  The role of the thymus in multiple sclerosis.

Authors:  V D'Andrea; G Meco; F Corvese; P F Baselice; V Ambrogi
Journal:  Ital J Neurol Sci       Date:  1989-02

4.  Prolonged azathioprine treatment of non-remitting multiple sclerosis.

Authors:  J A Rosen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-04       Impact factor: 10.154

5.  Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

6.  A double blind study on azathioprine efficacy in multiple sclerosis: final report.

Authors:  C Milanese; L La Mantia; A Salmaggi; M Eoli
Journal:  J Neurol       Date:  1993-05       Impact factor: 4.849

Review 7.  Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

Authors:  D E Goodkin
Journal:  West J Med       Date:  1994-09

8.  Clinical use of immunosuppressive drugs: part II.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

9.  Immunological treatment of multiple sclerosis.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

10.  Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results.

Authors:  C Milanese; L La Mantia; A Salmaggi; A Campi; C Bortolami; L Tajoli; A Nespolo; F Corridori
Journal:  Ital J Neurol Sci       Date:  1988-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.